Z1 Hip System

K251906 · Zimmer, Inc. · LZO · Jul 18, 2025 · Orthopedic

Device Facts

• Record ID: K251906
• Device Name: Z1 Hip System
• Applicant: Zimmer, Inc.
• Product Code: LZO · Orthopedic
• Decision Date: Jul 18, 2025
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 888.3353
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

Z1 Hip System is intended for total or hemi hip arthroplasty and is indicated for the following conditions: • Advanced wear of the joint due to degenerative, post-traumatic or rheumatic diseases. • Failed previous hip surgery including joint reconstruction (osteotomy), arthrodesis, hemi-arthroplasty or total hip replacement (THR). • Acute traumatic fracture of the femoral head or neck. • Avascular necrosis of the femoral head. Z1 Hip System is for cementless use only.

Device Story

Z1 Hip System consists of titanium alloy (Ti-6Al-4V) femoral stems for cementless implantation in proximal femur; wedge-shaped design with proximal-to-distal taper. Surface features include highly polished neck, grit-blasted body, plasma-sprayed Ti-6Al-4V coating, and hydroxyapatite (HA) overcoat. Stems mate with compatible femoral heads/adapters via 12/14 male taper. Available in multiple sizes, neck lengths, and offsets (standard, high, coxa vara), with collared or collarless options. Used by orthopedic surgeons in clinical settings for hip arthroplasty. System-specific instrumentation prepares femur. Device provides structural replacement for diseased/damaged hip joint, restoring joint function and mobility.

Clinical Evidence

No clinical testing was conducted. Substantial equivalence supported by non-clinical bench testing: distal fatigue testing (ISO 7206-4), proximal fatigue testing (ISO 7206-6), femoral head compatibility evaluation, and range of motion evaluation.

Technological Characteristics

Material: Ti-6Al-4V titanium alloy with hydroxyapatite (HA) overcoat. Design: Wedge-shaped femoral stem, proximal-to-distal taper, 12/14 male taper connection. Surface: Grit-blasted, plasma-sprayed. Sterilization: Provided sterile. Single-use. No software or electronic components.

Indications for Use

Indicated for patients requiring total or hemi hip arthroplasty due to degenerative, post-traumatic, or rheumatic joint wear; failed prior hip surgeries (osteotomy, arthrodesis, hemi-arthroplasty, or THR); acute traumatic femoral head/neck fractures; or avascular necrosis of the femoral head.

Regulatory Classification

Identification

A hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis is a device intended to be implanted to replace a hip joint. This device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. The two-part femoral component consists of a femoral stem made of alloys to be fixed in the intramedullary canal of the femur by impaction with or without use of bone cement. The proximal end of the femoral stem is tapered with a surface that ensures positive locking with the spherical ceramic (aluminium oxide, A12 03 ) head of the femoral component. The acetabular component is made of ultra-high molecular weight polyethylene or ultra-high molecular weight polyethylene reinforced with nonporous metal alloys, and used with or without bone cement.

Predicate Devices

• Z1 Hip System (K233476)

Submission Summary (Full Text)

{0}

FDA U.S. FOOD & DRUG ADMINISTRATION

July 18, 2025

Zimmer, Inc.
Erin Giffin
Regulatory Affairs Specialist
1800 West Center Street
Warsaw, Indiana 46580

Re: K251906
Trade/Device Name: Z1 Hip System
Regulation Number: 21 CFR 888.3353
Regulation Name: Hip Joint Metal/Ceramic/Polymer Semi-Constrained Cemented Or Nonporous Uncemented Prosthesis
Regulatory Class: Class II
Product Code: LZO, MEH, KWZ, KWY, LWJ
Dated: June 20, 2025
Received: June 20, 2025

Dear Erin Giffin:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

{1}

K251906 - Erin Giffin
Page 2

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-

{2}

K251906 - Erin Giffin
Page 3

assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

Limin Sun-S

Limin Sun, Ph.D.
Assistant Director
DHT6A: Division of Joint Arthroplasty Devices
OHT6: Office of Orthopedic Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

{3}

FORM FDA 3881 (8/23)
Page 1 of 1
PSC Publishing Services [phone]
EF

| DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use | Form Approved: OMB No. 0910-0120 Expiration Date: 07/31/2026 See PRA Statement below. |
| --- | --- |
| 510(k) Number (if known) K251906 | |
| Device Name Z1 Hip System | |
| Indications for Use (Describe) Z1 Hip System is intended for total or hemi hip arthroplasty and is indicated for the following conditions: • Advanced wear of the joint due to degenerative, post-traumatic or rheumatic diseases. • Failed previous hip surgery including joint reconstruction (osteotomy), arthrodesis, hemi-arthroplasty or total hip replacement (THR). • Acute traumatic fracture of the femoral head or neck. • Avascular necrosis of the femoral head. Z1 Hip System is for cementless use only. | |
| Type of Use (Select one or both, as applicable) ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | |
| CONTINUE ON A SEPARATE PAGE IF NEEDED. | |
| This section applies only to requirements of the Paperwork Reduction Act of 1995. *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* | |
| The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail] | |
| "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." | |

{4}

K251906
Page 1 of 3

510(k) Summary

Applicant:
Zimmer, Inc.
1800 W. Center Street
Warsaw, IN 46580, USA
Establishment Registration Number: 1822565

Contact Person:
Erin Giffin
Regulatory Affairs Specialist
Telephone: [phone])
Email: [e-mail]

Date:
July 17, 2025

Subject Device:
Trade Name: Z1 Hip System
510(k) Number: K251906
Common Name: Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis
Classification Name & Product Code:
LZO: Prosthesis, Hip, Semi-Constrained, Metal/Ceramic/Polymer, Cemented Or Non-Porous, Uncemented (21 CFR §888.3353)
MEH: Prosthesis, Hip, Semi-Constrained, Uncemented, Metal/Polymer, Non-Porous, Calcium Phosphate (21 CFR §888.3353)
KWZ: Prosthesis, Hip, Semi-Constrained, Cemented Or Uncemented, Metal/Polymer (21 CFR §888.3353)
KWY: Prosthesis, Hip, Hemi-, Femoral, Metal/Polymer, Cemented or Uncemented (21 CFR §888.3353)
LWJ: Prosthesis, Hip, Semi-Constrained, Cemented Or Uncemented, Metal/Polymer (21 CFR §888.3353)
Regulation Number: 888.3353

Predicate Device(s):
Predicate 510(k): K233476
Predicate Trade Name: Z1 Hip System
Product Code: LZO, MEH, KWZ, KWY, LWJ

Device Description Summary:
The Z1 Hip System consists of femoral hip stems intended for use in total or hemi hip arthroplasty. The stem is designed for cementless implantation in the proximal femur and mates with compatible femoral heads and adapters for use in total or hemi hip arthroplasty through a 12/14 male taper connection. The stems are manufactured from titanium alloy Ti-6Al-4V and have a wedge-shaped design, with a proximal-to-distal taper. Apart from the highly polished femoral neck region and the taper, the entire surface of the stem is grit-blasted, proximally sprayed with a Ti-6Al-4V titanium alloy plasma coating, and followed by a hydroxyapatite (HA)

{5}

K251906
Page 2 of 3

overcoat. Offered in multiple sizes and neck lengths, the stems are available in standard, high offset, and coxa vara offsets and as collared or collarless stems in each offset to accommodate various patient anatomies. The hip stems are provided sterile and are for single use only. System-specific instrumentation is available to prepare the femur for implantation of the Z1 Hip System femoral stems. The stems are compatible with previously cleared Zimmer Biomet modular femoral heads and/or acetabular components.

## Intended Use/Indications for Use:

Z1 Hip System is intended for total or hemi hip arthroplasty and is indicated for the following conditions:
- Advanced wear of the joint due to degenerative, post-traumatic or rheumatic diseases.
- Failed previous hip surgery including joint reconstruction (osteotomy), arthrodesis, hemi-arthroplasty or total hip replacement (THR).
- Acute traumatic fracture of the femoral head or neck.
- Avascular necrosis of the femoral head.

Z1 Hip System is for cementless use only.

## Indications for Use Comparison:

The subject device has the same intended use and indications for use as the predicate.

## Technological Comparison:

The technological characteristics of the subject device and predicate device are similar. The rationale for substantial equivalence is based on consideration of the following characteristics:
- Intended Use: Identical to the predicate device
- Indications for Use: Identical to the predicate device
- Raw Materials: Identical with modified processing
- Design Features: Identical to the predicate device
- Packaging: Identical to the predicate device
- Sterilization: Identical to the predicate device

## Non-Clinical and/or Clinical Tests Summary & Conclusions:

The following non-clinical testing and assessments were performed to support substantial equivalence:
- Distal Fatigue Testing per ISO 7206-4
- Proximal Fatigue Testing per ISO 7206-6
- Evaluation of Compatibility with Femoral Heads
- Evaluation of Range of Motion

No clinical testing was conducted.

{6}

K251906
Page 3 of 3

All non-clinical testing demonstrated that the new device is substantially equivalent to the predicate device.

**Substantial Equivalence Conclusion:**

Based on the information provided in this submission, the Z1 Hip System is substantially equivalent to the identified predicate device.